Gilead or Bust































(Reuters) - An independent committee recommended a late stage trial of a cancer drug developed by Pharmacyclics Inc and Johnson & Johnson be stopped early as it became clear it helped patients with chronic lymphocytic leukemia (CLL) live longer, paving the way for additional approval of the medicine.

The announcement of the study's early success by Pharmacyclics on Tuesday sent its shares soaring 20 percent higher and took J&J shares up by nearly 2 percent.

The independent monitoring committee, upon reviewing interim results of the trial called Resonate, unanimously recommended it be stopped as ibrutinib was deemed assured of meeting both the primary goal of significantly delaying progression of the disease and the secondary goal of extending survival in patients with relapsed CLL compared with those taking GlaxoSmithKline's Azerra (ofatumumab).

The committee also recommended that ibrutinib be made available to patients taking the Glaxo drug in the study.
 












Wow. the reps out there are scary these days. We need to go back to the 1990s. Good hard working people, having fun, drinking, be good reps to the docs, be there to help them out. good old days, what are the good for?
 












Wow. the reps out there are scary these days. We need to go back to the 1990s. Good hard working people, having fun, drinking, be good reps to the docs, be there to help them out. good old days, what are the good for?

The industry is contracting and it's brought out the worst in a lot of people. Plus, with all the regulation you can't really sell your product anymore. The good days are gone, never to return.. at least not in this field. Wish I was closer to retirement age. :( Good luck!